Currently, Genocea has the right to use Matrix M in vaccines targeting six infectious diseases including programs in its pipeline for herpes simplex virus type-2, Chlamydia trachomatis, and Streptococcus pneumoniae.
With this expansion, Genocea has got license to use Matrix M in vaccines for malaria and gonorrhoea.
Genocea CEO Chip Clark said a safe and effective adjuvant that elicits strong B and T cell immune response is essential to their aim to prevent or treat infectious diseases.
Isconova CEO Lena Soderstrom said they are pleased that a vaccine discovery and development company Genocea has selected Isconova’s Matrix M for use in two additional diseases, thus confirming the strengths of their products.